This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
AUA 2018
AUA 2018
Prostate Cancer
Bladder Cancer
Renal Cancer
Testis & Penile Cancers
Lower Urinary Tract Conditions – Nocturia
GU Reconstruction
Infections & Inflammation
Laparoscopic – Robotic Surgery
Sexual Function
Stone Disease
Press Releases
AUA 2018 Prostate Cancer
Viewing 61-80 of 109 articles
AUA 2018: Impact of Transient ADT with Leuprorelin 11.25 Mg on the Histological Progression of Indolent Prostate Cancer–Results of a Phase III Trial vs Active Surveillance
AUA 2018: Analysis of Methylated DNA Markers for Prediction of Cancer Progression after Radical Prostatectomy
AUA 2018: Four-year Follow-up of a Phase-3 Prospective Randomized Trial of Vascular-Targeted Phototherapy Versus Active Surveillance for Low-Risk Prostate Cancer
AUA 2018: MRI-Guided Transurethral Ultrasound Ablation (TULSA) in Patients with Localized Prostate Cancer: Preliminary Results of TACT Pivotal Study
AUA 2018: Validation of the Decipher Biopsy Test to Predict Adverse Pathology in Men Diagnosed with Low and Favorable Intermediate Risk Prostate Cancer
AUA 2018: The Men’s Eating and Living (MEAL) Study: A Randomized Clinical Trial of a Diet Intervention in Men on Active Surveillance for Prostate Cancer
AUA 2018: Biomarker Debate: Adopt, Expand, Trust (PRO)
AUA 2018: Biomarker Debate: Adopt, Expand, Trust (CON)
AUA 2018: Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018
AUA 2018: Performance Of Quantitative Gleason Grading: A Head to Head Comparison with CAPRA Score and D`Amico Groups
AUA 2018: Three Articles Last Year that Changed or Influenced My Practice
AUA 2018: Treatment of High-Risk Prostate Cancer - Surgery
AUA 2018: Treatment of High-Risk Prostate Cancer - Radiation
AUA 2018: Selection of Appropriate Genitourinary Cancers for Immunotherapy
AUA 2018: Debate - Should We Offer Active Surveillance for Gleason 7 (3+4) Risk Disease? (CON)
AUA 2018: Debate - Should We Offer Active Surveillance for Gleason 7 (3+4) Risk Disease? (PRO)
AUA 2018: Debate - Treatment of High Risk Advanced and M1 Disease: Is There a Role for Treatment of the Primary? (PRO)
AUA 2018: Debate - Treatment of High Risk Advanced and M1 Disease: Is There a Role for Treatment of the Primary? (CON)
AUA 2018: Prostate Cancer Biomarkers for Prognosis and Treatment Decision Making
AUA 2018: Risk Stratification for Active Surveillance: mp-MRI
1
2
3
4
5
6
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
